Abstract
Background: Heart failure is an increasing worldwide issue impacting 1-2% of the population and over 10% of older adults, resulting in high mortality rates. It is categorized by LVEF into HFrEF, HFmrEF, and HFpEF. Ramipril is effective but can lead to cough and kidney/electrolyte issues, whereas sacubitril+valsartan demonstrates improved results in HFrEF with increased hypotension. This study assesses both medications because of restricted local information. Methods & Materials: This study was a forward-looking comparative clinical trial carried out at Sir Salimullah Medical College and Mitford Hospital in Dhaka (January 2018-June 2019). A total of 100 post-MI HFrEF patients were randomly allocated to receive either sacubitril+valsartan or ramipril (50 each) and monitored for 3 months. Results showed enhancement in HF status and EF, with additional outcomes related to mortality, rehospitalization, medication discontinuation, and safety evaluation. Results: The baseline characteristics were comparable in both groups. Sacubitril+valsartan exhibited a more significant enhancement in NYHA class and EF, with fewer individuals in class III-IV (40% vs. 75%, p = 0.018) and an increased EF (34.96 ± 2.98 vs. 33.12 ± 3.32, p = 0.104). It also decreased rehospitalizations (6% compared to 22%, p = 0.018) and mortality rates (4% against 8%, p = 0.025), but resulted in higher hypotension incidence (18% compared to 8%). Other negative effects were reduced in the sacubitril+valsartan group (p = 0.027). Conclusion: Sacubitril+valsartan significantly improved NYHA functional class compared to ramipril after 3 months in post-MI HFrEF patients. It also showed lower rates of secondary outcomes and overall complications in patients received Sacubitril plus Valsartan.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 The Insight




PDF